Xenetic Biosciences (NASDAQ:XBIO) announced that its abstract has been accepted for poster presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting. The event will take place from November 6-10, 2024, in Houston, Texas and virtually.
The presentation details are as follows:
Title: DNase I Targeting of Neutrophil Extracellular Traps Improves CTLA-4 Immune Checkpoint blockade in Models of MSS/MMRp CRC
Abstract Number: 765
Presenter: Reid Bissonnette, Ph.D., Executive Consultant for Translational Research and Development at Xenetic
Date and Time: Friday, November 8, 2024, 9:00 a.m.-7:00 p.m. CST
Location: George R. Brown Convention Center -Level 1 -Exhibit Halls AB
102170281 : Hi what do u think of HOLO? should hold or sell??